Ozempic Not Working? The Common Reasons Weight Loss Stalls and What Doctors Check

A reader wrote to us in May describing the same week-after-week ritual: Sunday injection, Monday weigh-in, same number. She had switched from a compounded version to a branded pen after the US supply shortage was declared over in early 2025, and the switch seemed to coincide with the scale freezing. Her question was blunt. Was the medicine broken, or was she?

She is not alone. As of June 2025, searches for ozempic not working have climbed alongside a wave of patients changing products, pharmacies and prescribers, plus a steady stream of social posts claiming the drug simply fails for some people. The truth is more interesting, and more useful, than either the hype or the backlash.

Doctors who treat obesity have a checklist for exactly this situation. It covers dose, diet, timing, other medicines, sleep, hormones, technique and the ordinary biology of a body defending its weight. Most stalls land somewhere on that list. This article walks through it in the order clinicians usually do.

What changed recently: why ozempic not working is suddenly everywhere

Three dated events explain the current spike in worry. The first is old enough that people forget it: in February 2021 the STEP 1 trial, a randomized controlled study of semaglutide in adults with obesity, reported an average weight loss of 14.9 percent over 68 weeks against 2.4 percent with placebo. That headline number became the yardstick everyone measures themselves against, even though an average hides a wide spread.

The second is November 2023, when the SELECT trial showed that semaglutide reduced major cardiovascular events by about 20 percent in people with existing heart disease and overweight, and the US regulator added that heart protection claim to the Wegovy label in March 2024. That approval pulled the medicine into mainstream cardiology, and a much broader group of patients started on it with varied expectations.

The third is the one driving traffic right now. In early 2025 the US drug shortage for semaglutide was declared resolved, which started the wind-down of compounded copies that many people had been using. Patients who moved between products, or who paused while sorting out a new prescription, began noticing changes in appetite and progress. Some genuinely received a different amount of active drug; others simply hit the plateau that was always coming.

A quick definition helps from here. Semaglutide is a GLP-1 receptor agonist, meaning it mimics a gut hormone called glucagon-like peptide-1 that tells the brain you are full, slows the stomach from emptying and helps the pancreas release insulin after meals. Ozempic is the brand approved for type 2 diabetes; Wegovy is the same molecule approved for weight management. That distinction matters later, because the two are prescribed with different goals and different maximum doses.

What doctors mean when they say Ozempic is not working

The first thing a clinician does with a frustrated patient is define the problem, because ‘not working’ covers at least three different situations.

The first is early impatience: someone a few weeks in who expected the trial curve to start on day one. The second is a plateau, which is a stretch of several weeks where weight stops falling after a period of real loss. The third is true non-response, a term used when a person reaches the full treatment dose, stays on it for a reasonable trial period and still loses very little. Obesity medicine guidance commonly uses a benchmark of at least five percent of starting weight after roughly three months at the maintenance dose; below that, the medicine is considered to be underperforming for that person and the plan is reviewed.

Notice what that benchmark does not say. It does not count the months spent stepping the dose up, because early steps exist to limit nausea rather than to drive weight loss. It also does not use a single weigh-in. Doctors look at the trend line over four to six weeks, since day-to-day scale readings swing by several pounds with salt, carbohydrate intake, bowel habits, the menstrual cycle and hydration.

There is one more category worth naming: the person whose weight is stable but whose waist, blood sugar or blood pressure is improving. In the STEP trials, average waist circumference fell by more than five inches, and for someone with diabetes a steadier glucose reading may be the main goal. A flat scale does not always mean a flat result.

So the honest first question is not ‘why is it failing’ but ‘which of these am I in’. The answer changes everything that follows.

How long does Ozempic take to work, and when should you worry?

The appetite effect usually arrives first, often within the first couple of weeks, and it feels less like willpower and more like indifference: the second helping simply loses its pull. Weight follows more slowly, partly because the starting dose is low on purpose and is raised in steps over months under the prescriber’s direction.

The trial data are the best guide to pace. In STEP 1, the average participant lost weight steadily for about the first 60 weeks and then leveled off, with most of the loss concentrated in the middle months once the full dose was reached. A common question is how long it takes to lose 20 pounds. For a person starting at 200 pounds, 20 pounds is ten percent of body weight; trial averages reached that mark somewhere around the six to nine month point. For someone starting at 300 pounds the same 20 pounds is under seven percent and tends to come sooner. Individual results scatter widely around those averages, which is why doctors avoid promising dates.

Real-world data, which are observational rather than randomized, show lower average losses than the trials, often in the range of five to ten percent at one year. Part of that gap reflects people who stop early, miss injections or never reach the full dose. It is a reminder that the drug in a trial is taken consistently, with regular check-ins and structured lifestyle advice.

When should you worry? A reasonable rule, which most prescribers use, is to review the plan if there has been no meaningful change after about three months at the full dose, or if weight is actively climbing. Before that point, a flat scale is more often a dosing or timing issue than a signal that the medicine has failed.

Why am I not losing weight on Ozempic? Reason one: the dose and the product

This is the reason doctors check first, because it is the most common and the easiest to fix.

Ozempic is approved for type 2 diabetes, and its dosing is designed around blood sugar control. Wegovy is the same molecule approved for weight management, and its highest treatment dose is higher than the top diabetes dose. A person prescribed Ozempic for diabetes may be sitting at a dose that was never intended to produce trial-level weight loss. Using Ozempic specifically for weight in someone without diabetes is off-label, meaning outside the approved indication; the evidence for semaglutide and weight comes from the Wegovy trials, and whether and how to adjust the prescription is a decision for the treating clinician, not something to work around on your own.

Timing matters too. Many people judge the medicine during the step-up months, when the dose is deliberately modest. If nausea or other side effects have kept someone at an early step for longer than planned, that alone can explain a stall. The right response is a conversation with the prescriber about tolerability, not a self-directed jump.

Then there is the product itself. Compounded semaglutide, made by pharmacies outside the standard approval process, was legally permitted during the shortage but is not an approved medicine; concentration, purity and stability are not verified the way they are for the branded pens, and such products are not intended for self-use. People who switched from a compounded vial to a branded pen sometimes discover they had been receiving a different amount of active drug, in either direction. A prescriber can review exactly what was being taken and recalibrate.

Finally, missed injections quietly erode results. Semaglutide has a long half-life, but skipping doses while traveling or waiting on a refill lets appetite creep back, and a few lost weeks across a year adds up.

Reason two: the food pattern that appetite suppression does not reach

GLP-1 medicines quiet ‘food noise’, the background preoccupation with eating that many people with obesity describe. What they do not do is count calories. If intake stays close to what the body burns, the scale stays put, and there are several patterns that slip past reduced hunger.

Liquid calories are the classic one. Sweetened coffee drinks, juice, smoothies and alcohol do not trigger the same fullness as solid food, and slowed stomach emptying does little to blunt them. Alcohol in particular adds calories while loosening the resolve that makes the next meal smaller.

Grazing is another. People who feel too queasy for a proper meal may nibble crackers, toast and other soft, refined foods throughout the day. Each portion is small; the total is not. Dietitians who work with these patients often find that intake has shifted from three meals to a dozen snacks without anyone noticing.

Underestimation is universal, not a character flaw. Studies in which intake is measured against reported intake consistently find that people underreport by a substantial margin, often by a fifth or more. A week of honest tracking, including cooking oils, sauces and tastes while cooking, is one of the most informative tests a clinician can suggest.

Protein deserves a mention for a different reason. When appetite is low, protein is often the first thing to drop off the plate, and that accelerates muscle loss. In the STEP 1 body composition substudy, a meaningful share of the weight lost, roughly a third to 40 percent in some analyses, was lean tissue rather than fat. Keeping protein steady and lifting something heavy twice a week protects the muscle that keeps resting metabolism from sliding.

None of this means the medicine has failed. It means the medicine has opened a door that still has to be walked through.

Reason three: the ozempic plateau and why your body fights back

Every weight-loss method, from surgery to diet to injections, eventually meets the same wall. Doctors call it a plateau; biologists call it adaptive thermogenesis or metabolic adaptation, which simply means the body lowers its energy use as it shrinks, more than the smaller size alone would predict.

The arithmetic is unforgiving. A lighter body costs less to run, so a daily intake that produced loss at 220 pounds may be maintenance at 190. Hormones shift in the same direction: leptin, the fat-derived signal that tells the brain reserves are adequate, falls as fat mass falls, and hunger hormones such as ghrelin rise. GLP-1 medicines blunt this response, which is why plateaus arrive later and at a lower weight than with diet alone, but they do not abolish it. The STEP 1 curve itself flattened after about a year, and that was in a supervised trial.

Scale noise complicates the picture. Water shifts of three to five pounds within a week are common, driven by sodium, carbohydrate stores, constipation (a frequent side effect of these medicines) and, in women, the menstrual cycle. A single week without movement is not a plateau. Four to six weeks of a flat trend, with consistent dosing, is.

What breaks a plateau? The evidence favors boring answers: a fresh and honest look at intake, more daily movement rather than heroic workouts, resistance training to hold on to muscle, and sleep. The prescriber may also review whether the dose is at its maximum. What does not help is panic, skipping meals to the point of fatigue, or doubling down on cardio while protein collapses.

A plateau is also a chance to reframe. Weight that has been lost and held for months is, in medical terms, a success being maintained, not a failure in progress.

Reason four: other medicines and medical conditions that push the other way

When the first three reasons have been ruled out, clinicians widen the lens, because the stall sometimes has nothing to do with the injection.

Medicines that promote weight gain are a frequent culprit. Several antidepressants, most antipsychotics, some anti-seizure drugs, corticosteroids, certain beta-blockers and, in people with diabetes, insulin and sulfonylureas can all add pounds or make loss harder. None of these should be stopped or reduced without the prescriber’s involvement; the usual approach is a review of whether an alternative exists, not an abrupt switch.

Hypothyroidism, an underactive thyroid gland, slows metabolism modestly and can cause fatigue and fluid retention; a simple blood test for TSH (thyroid-stimulating hormone) checks it. Polycystic ovary syndrome, a hormonal condition that affects insulin handling, is common in women with obesity and can blunt progress. Cushing’s syndrome, an excess of cortisol, is rare but worth excluding when there are suggestive signs.

Sleep is underrated. Observational studies link short or fragmented sleep with higher appetite and weight, and obstructive sleep apnea, where breathing repeatedly pauses overnight, is both common in obesity and treatable. Loud snoring, morning headaches and daytime sleepiness are the usual prompts for a sleep study.

Mood and stress sit in the same category. Depression and chronic stress alter eating patterns and energy, and the hopelessness that follows a stall can itself feed the problem. A clinician will often ask about these not as an aside but as a core part of the assessment.

Menopause deserves its own line. Falling estrogen shifts fat storage toward the abdomen and slightly lowers energy expenditure. It does not make weight loss impossible, but it changes the pace and the shape of results, and expectations should be set accordingly.

Reason five: storage, technique and the small mechanics people overlook

A surprising number of stalls trace back to the pen itself.

Semaglutide is a protein-based medicine and it degrades with heat. Unopened pens are meant to be kept refrigerated until first use, and even in use they should be protected from direct sunlight and from hot environments such as a parked car. A pen that spent a summer afternoon in a bag may deliver a weakened dose with no visible change to the liquid. Anyone who suspects heat exposure should ask the pharmacist rather than guess.

Injection technique is next. The medicine is given under the skin, not into muscle, and rotating sites between the abdomen, thigh and upper arm helps absorption and reduces lumps or irritation. Pens come with a priming step on a new device and a hold time after pressing the button; cutting either short can leave part of the dose behind. The patient leaflet linked in the references describes the manufacturer’s steps, and a nurse or pharmacist can watch a practice injection.

Consistency of the weekly schedule also counts. Taking the injection on roughly the same day keeps blood levels steady; frequent long gaps allow appetite to rebound between doses, and people often eat more in those windows than they realize.

Then there is the question of what was actually in the pen or vial. During the shortage, products sold as semaglutide varied in concentration and quality, and some contained different salt forms or additives. Compounded and grey-market versions are not approved medicines, are not intended for self-use, and cannot be assumed equivalent to the branded product. A doctor assessing a stall will want to know exactly what was taken, from which source and for how long.

These are humble explanations, but they are fixable in a single appointment, which is more than can be said for most of the alternatives.

Semaglutide non-responder: what the evidence actually says

It helps to grade the evidence, because some of what circulates online is strong, some is weak and some is guesswork.

Strongest: randomized controlled trials. STEP 1 enrolled nearly 2,000 adults with obesity and no diabetes. Roughly 86 percent of those on semaglutide lost at least five percent of body weight, about 69 percent lost at least ten percent and about half lost at least 15 percent. Turn that around and about one in seven lost less than five percent despite a supervised trial with full dosing. In STEP 2, which enrolled people with type 2 diabetes, average losses were lower, closer to ten percent, which fits the broader observation that diabetes itself blunts the weight effect of these drugs. These are high-quality data and they establish two facts: most people respond, and a real minority respond only modestly.

Moderate: observational real-world cohorts. Studies drawn from clinic records consistently show lower average losses than trials, partly because of early discontinuation, missed doses and less structured support. They tell us how the drug performs in ordinary life, but they cannot cleanly separate the drug from the behavior around it.

Weaker: mechanistic and genetic hypotheses. Some early research suggests differences in GLP-1 receptor signaling or gut hormone profiles may explain why certain people respond less, and there is interest in whether baseline hunger patterns predict response. This is preliminary. No validated test currently tells a doctor in advance who will respond.

Expert opinion: the workup described in this article, the three-month benchmark and the decision to switch or combine medicines all rest on consensus guidance rather than head-to-head trials of strategies for non-responders. Guidance is sensible and widely used, but readers should know it is not the same grade of evidence as the trials.

The bottom line is unglamorous and reassuring: true non-response exists, is uncommon, and is a diagnosis of exclusion.

At a glance: the reasons Ozempic stalls and how each is checked

The table below compresses the clinical checklist into one view. It is not a self-diagnosis tool; it is a map of the conversation to expect, and a way to arrive at an appointment with the right information in hand.

Possible reason	Typical clue	What the doctor checks	Usual next step
Still on an early dose step	Weeks or a few months in; appetite only partly reduced	Current dose, how long at each step, side effects	Clinician-led review of the step-up plan
Prescribed for diabetes, not weight	On Ozempic with glucose as the main goal	Indication, glucose readings, weight goals	Discussion of whether a weight-management product is appropriate
Intake still matches expenditure	Snacking, liquid calories, alcohol, low protein	Food diary, dietitian review	Structured eating plan, protein target, strength training
Plateau after real loss	Flat trend after months of steady decline	Weight trajectory over the full course	Reset expectations, adjust intake and activity, confirm maximum dose
Another medicine	Started a new prescription around the stall	Full medication list	Prescriber considers alternatives; nothing stopped unilaterally
Hormonal or sleep condition	Fatigue, snoring, irregular cycles	TSH, screening for PCOS or sleep apnea	Treat the underlying condition
Storage or technique problem	Heat exposure, missed priming, long gaps	Pen handling, injection demonstration	Pharmacist review, consistent schedule
Compounded or uncertain product	Switched sources recently	Exactly what was taken and from where	Move to an approved product under supervision
Genuine low response	Under five percent after three months at full dose	Everything above excluded	Switch or combination therapy, decided by the clinician

Two patterns stand out. Most rows end with a conversation rather than a dramatic intervention, and the last row, true low response, is reached only after the others are crossed off. That order is the whole point of the checklist.

What doctors check when weight loss stalls on Ozempic

A good review appointment is more like detective work than a lecture, and it usually runs in a predictable order.

It starts with the timeline. When did the injections begin, how quickly was the dose raised, were any steps delayed by nausea, and how many doses were missed or late? A weight record over the whole period is worth more than any single number; the doctor is looking for the shape of the curve, not the last point on it.

Next comes the product history, which has become essential since the shortage ended. Branded pen or compounded vial, which supplier, any gaps while switching, how the medicine was stored. Honest answers here are not a confession; they are the data the clinician needs.

Then the eating pattern, ideally from a few days of tracking rather than memory, with particular attention to liquid calories, alcohol, snacking driven by nausea, and protein. Many clinics bring in a dietitian at this stage.

The medication list follows, with a careful eye on antidepressants, antipsychotics, steroids, insulin and other glucose-lowering drugs. Blood tests are modest: TSH to screen the thyroid, HbA1c (a three-month average of blood sugar) in anyone with or at risk of diabetes, and sometimes tests that reflect PCOS or cortisol excess if the history suggests them. A sleep questionnaire or referral for a sleep study is common when snoring or daytime sleepiness is present.

Some clinics measure body composition with a DXA scan or bioimpedance scale, which separate fat from lean tissue. These tools reveal when the scale is flat because muscle is being preserved while fat continues to fall, a situation that looks like failure on a bathroom scale and success on a body composition report.

Only after all of this does the conversation turn to changing the medicine, and that decision stays with the prescriber.

Why might Mounjaro stop working, and does switching help?

The same questions arrive about tirzepatide, sold as Mounjaro for type 2 diabetes and as Zepbound for weight management. Tirzepatide is a dual agonist, meaning it activates both the GLP-1 receptor and the GIP receptor, a second gut hormone pathway, and in the SURMOUNT-1 trial it produced average losses of roughly 15 to 21 percent over 72 weeks depending on the dose studied.

Does it stop working? The reasons for a stall are identical to those for semaglutide: dose steps, intake, plateau, other medicines, hormones, sleep, technique and product source. The plateau tends to arrive later and lower because the average effect is larger, but it arrives. People who switched from compounded tirzepatide to a branded product after the shortage period have reported the same confusion as semaglutide users, and the explanation is usually the same mix of dose uncertainty and timing.

Switching between the two is the more interesting question. A head-to-head randomized trial, SURMOUNT-5, reported in 2025 that tirzepatide produced greater average weight loss than semaglutide over 72 weeks in adults with obesity. That is strong evidence for a difference in average effect. It is not evidence that a person who responded modestly to one will respond strongly to the other; non-responders were not specifically studied, and individual response varies around both averages.

Guidance from obesity medicine specialists treats switching as reasonable when a person has had an adequate trial at full dose with little response, once the checklist has been completed. Combination approaches and newer agents are under study. Whether to switch, when, and to what is a decision for the treating clinician, informed by diabetes status, side effects, heart and kidney health and what has already been tried. Changing products on one’s own, or sourcing a second medicine outside a prescription, is neither safe nor supported by the evidence.

Common myths about Ozempic not working, corrected

Viral claims cluster around a few themes, and each has a factual answer.

Myth: it works for everyone, so if it fails the problem is you. Trials show about one in seven people lose under five percent despite full dosing. Low response is a biological reality, not a moral verdict, and it is uncommon rather than rare.

Myth: if you still feel hungry, the medicine is fake. Appetite reduction is partial, varies by dose step and fades somewhat between injections. Hunger on an early step is expected. Counterfeit and substandard products do exist, which is a reason to use an approved product through a prescription, but hunger alone proves nothing.

Myth: you do not need to change what you eat. Every trial that produced the headline numbers paired the drug with dietary counseling and activity advice. The drug makes a lower intake tolerable; it does not create one.

Myth: stopping and restarting resets the effect. There is no evidence for this. The STEP 1 extension study found that people who stopped semaglutide regained about two-thirds of lost weight within a year, which argues for continuity, not cycling.

Myth: the drug burns fat directly. It acts on appetite, stomach emptying and insulin, not on fat cells. Weight falls because intake falls. That is also why muscle can be lost alongside fat unless protein and strength training are protected.

Myth: a plateau means the drug has worn off. Receptor tolerance has not been demonstrated in the trials; plateaus reflect the body’s adaptation to a lower weight. Weight generally stays off while treatment continues, which is the definition of a maintenance phase.

Myth: more is always better. Higher doses raise side effects, and any change belongs to the prescriber. Self-escalation, especially with products of uncertain strength, is where emergency visits for vomiting and dehydration tend to come from.

What is the fastest way to lose weight? An honest answer

People searching this phrase usually want a number, so here is the evidence-based one: a sustained loss of about one to two pounds per week is the pace that public health bodies describe as both achievable and more likely to be kept off. Faster is possible, especially early on when water weight falls, but speed has costs.

The first cost is muscle. Rapid loss without adequate protein and resistance training strips lean tissue, which lowers resting energy expenditure and makes the eventual plateau arrive sooner and harder. The second is gallstones; quick weight loss, by any method, raises the risk of gallbladder problems, which is one reason sudden right-sided upper abdominal pain is on the red-flag list. The third is adherence. Crash approaches end, and the regain that follows is well documented in observational and trial data alike.

On a GLP-1 medicine the question changes slightly. The drug sets a ceiling on how much appetite will cooperate; the job is to make the calories that remain count. Three habits carry most of the evidence. Protein at each meal, because it preserves muscle and is the most filling macronutrient per calorie. Strength training two or three times a week, which the trials did not require and which most experts now wish they had. Seven or more hours of sleep, since short sleep reliably raises hunger hormones in controlled studies.

Movement outside the gym matters more than many people expect. Daily steps, standing, stairs and chores make up a large share of energy expenditure and tend to fall when people feel tired or queasy on a new medicine. Keeping that background activity steady is quietly powerful.

The fastest way, in other words, is the way you can still be doing in two years. Everything else is a loan against future regain.

When to see a doctor about Ozempic not working or new symptoms

Two kinds of appointment matter here: the planned review when progress stalls, and the urgent visit when something feels wrong.

Book a routine review if there has been no meaningful change after about three months at the full prescribed dose, if weight is rising rather than flat, if side effects have kept the dose from being raised as planned, or if you switched products or sources during the shortage and are unsure what you were taking. Bring your weight record, a few days of food tracking, your full medication list and the pen or packaging. Never adjust the dose, skip steps, stop the medicine or add a second product without the prescriber’s agreement; that applies equally to people using Ozempic for diabetes, where stopping can affect blood sugar.

Seek same-day or emergency care for any of the following:

• Severe, persistent abdominal pain, especially radiating to the back, with or without vomiting, which can signal pancreatitis.
• Vomiting that prevents keeping fluids down, dizziness on standing, or very little urine, which point to dehydration and possible kidney strain.
• Pain in the upper right abdomen, fever, or yellowing of the skin or eyes, which can indicate gallbladder disease.
• In people with diabetes, symptoms of low blood sugar such as shaking, sweating, confusion or fainting, particularly if also taking insulin or a sulfonylurea.
• Sudden changes in vision, which require prompt eye assessment in anyone with diabetes.
• A lump or swelling in the neck, trouble swallowing or persistent hoarseness, which the prescriber will want to examine.
• Swelling of the face, lips or throat, hives or difficulty breathing, which are signs of a serious allergic reaction.
• New or worsening low mood or thoughts of self-harm.

Rapid heartbeat, severe constipation lasting more than a few days, or stomach pain that is milder but will not settle also deserve a prompt call. Everything about dose, product and whether to continue belongs to the clinician who prescribed the medicine; this article is a guide to the conversation, not a substitute for it.

Frequently asked questions

Why is my weight loss not working on Ozempic?

The most common reasons are that the dose is still being stepped up, calorie intake has quietly stayed near maintenance through snacking or drinks, a plateau has arrived after earlier losses, another medicine or a condition such as hypothyroidism or sleep apnea is interfering, or the pen was stored or used incorrectly. A prescriber works through these in order before considering a genuine low response.

Why am I not losing weight on Ozempic even though I eat less?

Reduced appetite does not guarantee reduced calories. Liquid calories, alcohol, frequent small snacks and cooking fats slip past fullness signals, and most people underestimate intake substantially. A lighter body also burns fewer calories, so an intake that worked earlier may now be maintenance. A few days of honest tracking, reviewed with a clinician or dietitian, usually reveals the gap.

How long does Ozempic take to work for weight loss?

Appetite usually changes within the first couple of weeks, while meaningful weight loss builds over months as the dose is raised under the prescriber’s direction. In trials, average loss continued for about a year before leveling off. Doctors typically reassess if there is no real change after roughly three months at the full dose.

How long will it take to lose 20 lbs on Ozempic?

It depends on starting weight. For someone at 200 pounds, 20 pounds is ten percent of body weight, which trial averages reached around six to nine months after starting. For a heavier person the same 20 pounds is a smaller percentage and may come sooner. Individual pace varies widely, so clinicians avoid promising a date.

What is an ozempic plateau and how long does it last?

A plateau is a stretch of four to six weeks or more with no downward trend despite consistent dosing. It reflects the body adapting to a lower weight by burning fewer calories and raising hunger signals. Plateaus can last weeks to months; adjusting intake, adding strength training, improving sleep and confirming the dose with the prescriber are the usual responses.

Can you be a semaglutide non-responder?

Yes. In randomized trials about one in seven participants lost less than five percent of body weight despite full dosing and support. True non-response is a diagnosis of exclusion made after dose, diet, other medicines, hormones, sleep, technique and product source have been reviewed. No test currently predicts it in advance; the next step is decided by the treating clinician.

Why might Mounjaro stop working?

The reasons mirror those for Ozempic: an early dose step, intake drifting back up, a natural plateau, interfering medicines or conditions, missed or late injections, heat-damaged pens, or uncertainty about what a compounded product actually contained. Tirzepatide produces larger average losses, so plateaus tend to arrive later, but the body’s adaptation to a lower weight still happens.

What is the fastest way to lose weight safely?

Public health guidance describes a sustained one to two pounds per week as the pace most likely to be kept off. Faster loss raises the risk of muscle loss and gallstones and is usually followed by regain. On a GLP-1 medicine, protein at each meal, strength training, adequate sleep and steady daily movement produce the best results within whatever appetite the drug allows.

Does Ozempic stop working after a while?

Trials show no evidence that the medicine loses its effect at the receptor level. What people experience as it wearing off is the plateau that follows real weight loss, when the body defends its new, lower weight. Weight generally stays off while treatment continues, and in the extension study most regained weight after stopping.

What tests do doctors run when Ozempic is not working?

A typical workup includes a review of the dose history, product source, food pattern and full medication list, plus blood tests such as TSH for thyroid function and HbA1c for average blood sugar. Depending on symptoms, screening for PCOS, cortisol excess or sleep apnea may follow. Some clinics also measure body composition to see whether fat is falling while muscle is preserved.

References

• Semaglutide Injection: MedlinePlus Drug Information
• Obesity: Treatment: NHS

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.